In combined resection of the bladder and ureter during laparoscopic surgery for gynaecological recurrent cancer, some cases require laparoscopic ureteral reconstruction techniques. In the open surgery approach, it has been reported that gynaecological advanced or recurrent tumour surgeries solely conducted by a gynaecologic group, with combined resection of multiple organs, improves the prognosis. However, to the best of our knowledge, in the minimally invasive surgery approach, there are no reported case series in the field of gynaecological recurrent tumour surgery conducted by only a gynaecologic group, with combined resection of the bladder and ureter. Therefore, we conducted this pilot study to describe the feasibility of laparoscopic gynaecologic recurrent malignant tumour surgery involving ureteral reconstruction. We retrospectively searched our patient database for women with gynaecological cancer who underwent laparoscopic ureteral reconstruction techniques in gynaecological recurrent cancer surgeries. Nine patients underwent laparoscopic ureteral reconstruction for long-segment ureteral defects in gynaecologic surgeries. In all cases, R0 surgical resection were successfully performed. The ureteral defect lengths ranged from 3.5-10 cm (median, 4 cm). The Boari flap was necessary in one of the eight cases with a ureteral defect of less than 8 cm. The ureteral defect was less than 12 cm in all cases, but substitution was required in three cases. In all cases except one, no urinary complications occurred. In conclusion, it is feasible for a gynaecologist to perform laparoscopic ureteral reconstruction combined resection of the bladder and ureter during laparoscopic surgery for gynaecological recurrent cancer.
Cite this article
Laparoscopic ureteral reconstruction in gynaecological recurrent cancer surgeries: an initial case series study
Yuji Tanaka1, Yusuke Shimizu1, Ai Ikki1, Kota Okamoto1, Atsushi Fusegi1, Makoto Nakabayashi1, Makiko Omi1, Tomoko Kurita1, Terumi Tanigawa1, Yoichi Aoki1, Sachiho Netsu1, Mayu Yunokawa1, Hidetaka Nomura1, Maki Matoda1, Sanshiro Okamoto1, Kohei Omatsu1, Hiroyuki Kanao1,*
1 Department of Gynecologic Oncology, Cancer Institute Hospital of JFCR, Koutouku, 135-8550, Tokyo, Japan
Eur. J. Gynaecol. Oncol. 2020, 41(6), 975–981; https://doi.org/10.31083/j.ejgo.2020.06.2258
Accepted: 5 November 2020 | Published: 15 December 2020
Copyright: © 2020 Published by IMR press. All rights reserved.
This is an open access article under the CC BY-NC 4.0 license